Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of bomedemstat vs Best Available Therapy in Essential Thrombocythemia After Hydroxyurea
jRCT2031230658Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in thrombocythemia (2 arms), sponsored by Merck & Co. Primary endpoint: DCHR. Started May 2024; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on jRCT2031230658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230658.